RESUMO
ObjectiveTo evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with argon-helium cryoablation in patients with advanced unresectable primary hepatocellular carcinoma (HCC). MethodsTACE was performed in 35 patients with primary HCC who were admitted to our hospital from May 2008 to June 2010. After 2-3 weeks of treatment, the patients received argon-helium cryoablation, followed by a second TACE in 1-2 weeks. The short-term efficacy after treatment was evaluated and the long-term survival was studied by follow-up. Comparison between two groups was made by t test, and survival was analyzed using the Kaplan-Meier survival curves. ResultsThe clinical outcomes of all 35 patients were evaluated. Complete response was observed in 7 patients, partial response in 21 patients, stable disease in 4 patients, and progressive disease in 3 patients. The overall response rate was 80.00%, and the disease control rate was 91.43%. The 2- and 3-year survival rates were 45.6% and 39.4%, respectively. The level of alpha-fetoprotein AFP in patients after the treatment (206.2±48.6 μg/L) was significantly lower than that before the treatment (837.6±216.7 μg/L) (t=2.673, P＜0.05). ConclusionTACE combined with argon-helium cryoablation is a reliable therapeutic approach in treating advanced unresectable primary HCC, and the advantages include minimal invasion, fast recovery, and few complications.
RESUMO
Objective To compare the efficacy and toxicity of late-course concurrent radiochemotherapy and sequential chemoradiotherapy for advanced esophageal carcinoma. Methods Eighty-two patients with advanced esophageal carcinoma were randomized into two groups: 41 cases in late-course concurrent radiochemotherapy (LCRC) group were received two cycles chemotherapy and then underwent concurrent radiochemotherapy;41 cases in sequential chemoradiotherapy (SCR) group were received four cycles chemotherapy and then underwent radiotherapy. The regimen of chemotherapy in all cases:cisplatin 25mg/m2, 1-3 d;calcium folinate (CF) 150 mg/m2, 1-5 d;fluorouracil 375 mg/m2, 1-5 d, 21 d was one cycle. All patients were received the three-dimensional conformal radiation therapy, the total dose of radiation was same as 64 Gy. Results The short-term response rate was 85.4%(35/41) in LCRC group and 65.9%(27/41) in SCR group, they had significant difference ( P0.05). The l year, 2 years, 3 years survival rate were 68.3%(28/41) and 65.9%(27/41), 56.1%(23/41) and 51.2%(21/41), 46.3%(19/41) and 36.6%(15/41) respectively,the median survival time were 30.0 months and 26.0 months, there had no significant difference ( P>0.05). Conclusion The short-term efficacy of advanced esophageal carcinoma could be improved by the late-course concurrent radiochemotherapy.
RESUMO
Objective To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE)combined with argon-heli-um cryoablation in patients with advanced unresectable primary hepatocellular carcinoma (HCC).Methods TACE was performed in 35 patients with primary HCC who were admitted to our hospital from May 2008 to June 2010.After 2-3 weeks of treatment,the patients re-ceived argon-helium cryoablation,followed by a second TACE in 1 -2 weeks.The short-term efficacy after treatment was evaluated and the long-term survival was studied by follow-up.Comparison between two groups was made by t test,and survival was analyzed using the Kaplan-Meier survival curves.Results The clinical outcomes of all 35 patients were evaluated.Complete response was observed in 7 pa-tients,partial response in 21 patients,stable disease in 4 patients,and progressive disease in 3 patients.The overall response rate was 80. 00%,and the disease control rate was 91.43%.The 2-and 3-year survival rates were 45.6% and 39.4%,respectively.The level of alpha-fetoprotein AFP in patients after the treatment (206.2 ±48.6 μg/L)was significantly lower than that before the treatment (837.6 ± 216.7 μg/L)(t=2.673,P<0.05).Conclusion TACE combined with argon-helium cryoablation is a reliable therapeutic approach in treating advanced unresectable primary HCC,and the advantages include minimal invasion,fast recovery,and few complications.
RESUMO
ObjectiveTo evaluate the efficacy and safety of transcatheter arterial chemoembolization combined with argon-helium cryoablation on patients with advanced unresectable primary hepatocellular carcinoma. MethodsTranscatheter arterial chemoembolization was performed in 35 patients with primary hepatocellular carcinoma,then argon-helium cryoablation was done after 2-3 weeks.The second transcatheter arterial chemoembolization treatment was performed 1-2 week after argon-helium cryoablation.The after treatment response was evaluated and the toxicity was observed.RusultsThirty-five patients were evaluated.Complete response was observed in 7 patients,partial response in 21 patients,stable disease in 4 patients and progressive disease in 3 patients. Overall response rate was 80.00 ％(2g/35), and disease control rate was 91.43 ％(32/35). Patients' median PFS was 8.9 months, median OS was 16.3 months. ConclusionThe therapeutic effect of transcatheter arterial chemoembolization combined with argon-helium cryoablation is good in treating advanced unresectable primary hepatocellular carcinoma.